Plus Therapeutics (PSTV) Shares Outstanding (Weighted Average) (2010 - 2026)

Plus Therapeutics (PSTV) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $6.6 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $6.6 million, up 1040.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 1040.62% YoY), and the FY2025 annual result was $77.8 million, up 751.02% from the prior year.
• Shares Outstanding (Weighted Average) slipped to $6.6 million in Q1 2026 per PSTV's latest filing, from $77.8 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $107.4 million in Q3 2025 and troughed at $582668.0 in Q1 2025.
• A 5-year average of $16.9 million and a median of $3.1 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 1267.52% in 2025 and fell as far as 86.52% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $1.8 million in 2022, then surged by 79.45% to $3.1 million in 2023, then jumped by 191.08% to $9.1 million in 2024, then surged by 751.02% to $77.8 million in 2025, then slumped by 91.46% to $6.6 million in 2026.
• Business Quant data shows PSTV's Shares Outstanding (Weighted Average) at $6.6 million in Q1 2026, $77.8 million in Q4 2025, and $107.4 million in Q3 2025.